Samsung has announced a collaborative research initiative with the Massachusetts General Hospital (MGH) Diabetes Research Centre to investigate how wearable technology can assist patients on GLP-1 medications in managing muscle loss. The clinical study will leverage the Galaxy Watch 8, which launched last year, alongside the Samsung Health ecosystem. Researchers plan to evaluate the feasibility of mitigating lean muscle decline by tracking continuous biometric indicators, including body composition, physical activity metrics, and heart rate data.
Read: SpaceX successfully launches Starship V3 in performance-packed test flight
The integration comes amid a massive surge in GLP-1 adoption; Samsung referenced a KFF poll indicating that nearly one in five adults in the United States has used a GLP-1 agonist to manage Type 2 diabetes or facilitate weight loss. However, long-term physiological impacts remain a subject of intense scientific scrutiny. According to Dr. David N. Brennan of the Mayo Clinic, emerging data shows that over 30 percent of the total weight shed on these medications can stem directly from muscle mass. While muscle loss accompanies most rapid weight-reduction methods, clinicians are particularly concerned that patients failing to maintain lean mass may experience diminished physical capabilities, a lowered basal metabolic rate, and rapid fat regain after terminating treatment. Furthermore, researchers from the University of Virginia warned that losing crucial axial muscle compromises posture and increases long-term cardiovascular risks.
Led by Dr. Melissa Putman of the MGH Diabetes Research Centre, the study will enrol 100 adults who are just initiating a GLP-1 therapeutic regimen. The cohort will be split into two distinct testing groups:
- The Wearable Group: Participants will utilize the Galaxy Watch 8’s built-in Bioelectrical Impedance Analysis (BIA) sensor to monitor fluctuating body composition, track daily activity levels, and follow personalized, data-driven exercise guidance tailored to preserve lean muscle.
- The Control Group: Participants will receive standard clinical guidance typically provided to patients undergoing conventional GLP-1 therapy.
See also
To evaluate the true efficacy of the wearable platform, researchers will validate the smartwatches’ continuous data streams against clinical-grade dual-energy X-ray absorptiometry (DXA) body scans. “We’re interested in exploring how continuous data from a wearable device can provide invaluable insights… allowing for more timely, data-driven adjustments to their care plan,” Dr. Putman stated.
This initiative aligns with Samsung’s broader strategy of executing clinical trials with academic medical institutions to expand its wearable health features. The tech company previously collaborated with Stanford University to refine its sleep apnoea detection algorithms and recently worked with South Korea’s Chung-Ang University Gwangmyeong Hospital to develop a highly accurate syncope prediction framework.
